BCRX Stock Forecast 2025-2026
Distance to BCRX Price Targets
BCRX Price Momentum
10 Quality Stocks Worth Considering Now
Researching BioCryst (BCRX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BCRX and similar high-potential opportunities.
Latest BCRX Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, BCRX has a bullish consensus with a median price target of $12.00 (ranging from $8.00 to $30.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $8.07, the median forecast implies a 48.7% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew Fein at HC Wainwright & Co., projecting a 271.7% upside. Conversely, the most conservative target is provided by Gena Wang at Barclays, suggesting a 0.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BCRX Analyst Ratings
BCRX Price Target Range
Latest BCRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BCRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 3, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $18.00 |
| Feb 25, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $30.00 |
| Feb 25, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $11.00 |
| Feb 25, 2025 | Citizens Capital Markets | Jonathan Wolleben | Market Outperform | Reiterates | $18.00 |
| Jan 31, 2025 | JMP Securities | Jonathan Wolleben | Market Outperform | Reiterates | $18.00 |
| Jan 13, 2025 | Needham | Serge Belanger | Buy | Maintains | $15.00 |
| Jan 13, 2025 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $12.00 |
| Dec 17, 2024 | Needham | Serge Belanger | Buy | Maintains | $15.00 |
| Nov 5, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $10.00 |
| Nov 5, 2024 | Needham | Serge Belanger | Buy | Reiterates | $14.00 |
| Nov 5, 2024 | Barclays | Gena Wang | Equal-Weight | Maintains | $8.00 |
| Aug 6, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $16.00 |
| Aug 6, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $30.00 |
| Aug 6, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $10.00 |
| Aug 6, 2024 | Barclays | Gena Wang | Equal-Weight | Maintains | $7.00 |
| May 7, 2024 | JMP Securities | Jonathan Wolleben | Market Outperform | Maintains | $15.00 |
| May 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $30.00 |
| May 7, 2024 | Needham | Serge Belanger | Buy | Reiterates | $12.00 |
| Apr 10, 2024 | Needham | Serge Belanger | Buy | Reiterates | $12.00 |
| Jan 8, 2024 | Needham | Serge Belanger | Buy | Reiterates | $12.00 |
BioCryst Pharmaceuticals Inc. (BCRX) Competitors
The following stocks are similar to BioCryst based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BioCryst Pharmaceuticals Inc. (BCRX) Financial Data
BioCryst Pharmaceuticals Inc. has a market capitalization of $1.68B with a P/E ratio of -18.2x. The company generates $450.71M in trailing twelve-month revenue with a -19.7% profit margin.
Revenue growth is +40.8% quarter-over-quarter, while maintaining an operating margin of -3.4% and return on equity of +18.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
BioCryst Pharmaceuticals Inc. (BCRX) Business Model
About BioCryst Pharmaceuticals Inc.
Develops novel medicines for rare diseases.
BioCryst Pharmaceuticals generates revenue through the discovery and development of innovative oral, small-molecule drugs targeting rare diseases. By focusing on conditions with limited treatment options, the company aims to bring new therapeutics to market, which can lead to significant financial returns as these products gain approval and adoption in the healthcare sector.
With a strong emphasis on structure-based drug design, BioCryst is positioned in the rapidly growing biotech industry, which is known for its potential for scientific breakthroughs and market growth. Their commitment to addressing unmet medical needs not only enhances patient outcomes but also solidifies their role as a key player in the healthcare landscape.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
580
CEO
Mr. Jon P. Stonehouse
Country
United States
IPO Year
1994
Website
www.biocryst.comBioCryst Pharmaceuticals Inc. (BCRX) Latest News & Analysis
BioCryst Pharmaceuticals granted 65,900 restricted stock units to seven new employees as inducements for joining the company. This was effective March 3, 2025, in line with Nasdaq regulations.
BioCryst's grant of RSUs to new hires signals confidence in its growth strategy, potentially enhancing employee retention and aligning interests with shareholders, which may positively impact stock performance.
BioCryst (BCRX) released its revenue and EPS for Q4 2024. Investors should compare these figures with Wall Street estimates and year-ago results for a comprehensive analysis.
Comparing BioCryst's revenue and EPS to Wall Street estimates and prior year figures can indicate growth potential, market confidence, and future stock performance, influencing investment decisions.
BioCryst Pharmaceuticals, Inc. (BCRX) announced interim analysis results from its ongoing APeX-P trial on Monday.
The interim analysis of the APeX-P trial could impact BioCryst's stock price and investor sentiment, indicating potential advancements or setbacks in drug development.
BioCryst Pharmaceuticals (BCRX) shares fell 10% on Monday following the release of its fourth-quarter and full-year 2024 results, indicating investor disappointment.
BioCryst Pharmaceuticals' 10% drop indicates negative market sentiment following its Q4 and full-year results, signaling potential concerns over performance and future growth prospects.
BioCryst Pharmaceuticals will hold its Q4 2024 Earnings Conference Call on February 24, 2025, at 8:30 AM ET, featuring key executives and analysts from major financial institutions.
BioCryst's Q4 earnings call could reveal critical insights on financial performance and future guidance, influencing stock valuation and investor sentiment.
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
1 month agoORLADEYO reported Q4 2024 net revenue of $124.2 million, a 36.6% increase year-over-year, and FY 2024 net revenue of $437.7 million, up 34.3% year-over-year.
Strong revenue growth for ORLADEYO indicates robust demand and potential market expansion, positively impacting investor confidence and stock valuation.
Frequently Asked Questions About BCRX Stock
What is BioCryst Pharmaceuticals Inc.'s (BCRX) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, BioCryst Pharmaceuticals Inc. (BCRX) has a median price target of $12.00. The highest price target is $30.00 and the lowest is $8.00.
Is BCRX stock a good investment in 2025?
According to current analyst ratings, BCRX has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BCRX stock?
Wall Street analysts predict BCRX stock could reach $12.00 in the next 12 months. This represents a 48.7% increase from the current price of $8.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is BioCryst Pharmaceuticals Inc.'s business model?
BioCryst Pharmaceuticals generates revenue through the discovery and development of innovative oral, small-molecule drugs targeting rare diseases. By focusing on conditions with limited treatment options, the company aims to bring new therapeutics to market, which can lead to significant financial returns as these products gain approval and adoption in the healthcare sector.
What is the highest forecasted price for BCRX BioCryst Pharmaceuticals Inc.?
The highest price target for BCRX is $30.00 from Andrew Fein at HC Wainwright & Co., which represents a 271.7% increase from the current price of $8.07.
What is the lowest forecasted price for BCRX BioCryst Pharmaceuticals Inc.?
The lowest price target for BCRX is $8.00 from Gena Wang at Barclays, which represents a -0.9% decrease from the current price of $8.07.
What is the overall BCRX consensus from analysts for BioCryst Pharmaceuticals Inc.?
The overall analyst consensus for BCRX is bullish. Out of 11 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are BCRX stock price projections?
Stock price projections, including those for BioCryst Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
